Cargando…
Tumor targeting using liposomal antineoplastic drugs
During the last years, liposomes (microparticulate phospholipid vesicles) have been used with growing success as pharmaceutical carriers for antineoplastic drugs. Fields of application include lipid-based formulations to enhance the solubility of poorly soluble antitumor drugs, the use of pegylated...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526358/ https://www.ncbi.nlm.nih.gov/pubmed/18488413 |
_version_ | 1782158738475450368 |
---|---|
author | Huwyler, Jörg Drewe, Jürgen Krähenbühl, Stephan |
author_facet | Huwyler, Jörg Drewe, Jürgen Krähenbühl, Stephan |
author_sort | Huwyler, Jörg |
collection | PubMed |
description | During the last years, liposomes (microparticulate phospholipid vesicles) have been used with growing success as pharmaceutical carriers for antineoplastic drugs. Fields of application include lipid-based formulations to enhance the solubility of poorly soluble antitumor drugs, the use of pegylated liposomes for passive targeting of solid tumors as well as vector-conjugated liposomal carriers for active targeting of tumor tissue. Such formulation and drug targeting strategies enhance the effectiveness of anticancer chemotherapy and reduce at the same time the risk of toxic side-effects. The present article reviews the principles of different liposomal technologies and discusses current trends in this field of research. |
format | Text |
id | pubmed-2526358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-25263582008-09-04 Tumor targeting using liposomal antineoplastic drugs Huwyler, Jörg Drewe, Jürgen Krähenbühl, Stephan Int J Nanomedicine Review During the last years, liposomes (microparticulate phospholipid vesicles) have been used with growing success as pharmaceutical carriers for antineoplastic drugs. Fields of application include lipid-based formulations to enhance the solubility of poorly soluble antitumor drugs, the use of pegylated liposomes for passive targeting of solid tumors as well as vector-conjugated liposomal carriers for active targeting of tumor tissue. Such formulation and drug targeting strategies enhance the effectiveness of anticancer chemotherapy and reduce at the same time the risk of toxic side-effects. The present article reviews the principles of different liposomal technologies and discusses current trends in this field of research. Dove Medical Press 2008-03 2008-03 /pmc/articles/PMC2526358/ /pubmed/18488413 Text en © 2008 Dove Medical Press Limited. All rights reserved |
spellingShingle | Review Huwyler, Jörg Drewe, Jürgen Krähenbühl, Stephan Tumor targeting using liposomal antineoplastic drugs |
title | Tumor targeting using liposomal antineoplastic drugs |
title_full | Tumor targeting using liposomal antineoplastic drugs |
title_fullStr | Tumor targeting using liposomal antineoplastic drugs |
title_full_unstemmed | Tumor targeting using liposomal antineoplastic drugs |
title_short | Tumor targeting using liposomal antineoplastic drugs |
title_sort | tumor targeting using liposomal antineoplastic drugs |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526358/ https://www.ncbi.nlm.nih.gov/pubmed/18488413 |
work_keys_str_mv | AT huwylerjorg tumortargetingusingliposomalantineoplasticdrugs AT drewejurgen tumortargetingusingliposomalantineoplasticdrugs AT krahenbuhlstephan tumortargetingusingliposomalantineoplasticdrugs |